Chemomab Therapeutics

Chemomab is a clinical stage biotech company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Nasdaq: $CMMB

[Chemomab Therapeutics @ChemomabTx]

Dr. Adi Mor, Chemomab co-founder and CEO, will present a corporate presentation at BIOMED Israel 2025 in Tel Aviv, on May 21, 2025 in a session in Hall A from 12:15-14:15 IDT. For conference details, please visit: https://t.co/TjmGwoxJxy $CMMB

[Chemomab Therapeutics @ChemomabTx]

Dr. Adi Mor, Chemomab co-founder and CEO, will present a virtual corporate presentation on May 21st from 9:30 AM-10 AM ET during the Aegis Capital Corp. Virtual Conference. Institutional investors and registered representatives are invited to join: https://t.co/lT5ugFluCt $CMMB

[Chemomab Therapeutics @ChemomabTx]

The second was the release of positive 48-week data from the nebokitug Ph. 2 SPRING trial, confirming & building on 15-week results. Patients w/ moderate to advanced PSC showed continued improvements in key liver injury, inflammation & fibrosis biomarkers. https://t.co/rhrrjqEk8N

[Chemomab Therapeutics @ChemomabTx]

Read full comments from Adi Mor, PhD, co-founder, Chief Executive Officer, and Chief Scientific Officer of Chemomab, on the Company’s achievement of two major milestones with transformative potential in the first quarter of 2025: https://t.co/8Ee4bxKUqq $CMMB

[Chemomab Therapeutics @ChemomabTx]

The first milestone was achieving, for the first time, a clear regulatory pathway with the FDA to advance nebokitug to a potential full regulatory approval in PSC. For more clinical highlights, visit: https://t.co/8Ee4bxKUqq $CMMB

[Chemomab Therapeutics @ChemomabTx]

Chemomab Therapeutics today announced financial and operating results for the first quarter ended March 31, 2025, and provided a corporate update. For details: https://t.co/8Ee4bxKUqq $CMMB

[Chemomab Therapeutics @ChemomabTx]

SPRING trial data presented at #DDW25 shows that nebokitug at 15 and 48 weeks of treatment is well-tolerated & associated with significant improvements in multiple fibrotic & inflammatory biomarkers that may represent slowing of disease progression. https://t.co/7zm5UjFOwK $CMMB

[Chemomab Therapeutics @ChemomabTx]

Paul J. Pockros, MD, Director, Liver Disease Center Scripps Clinic, Director of the SC Liver Research Consortium, & SPRING trial investigator, presented positive Ph. 2 SPRING trial data at #DDW25. Read his comments on nebokitug’s clinical potential: https://t.co/7zm5UjFOwK $CMMB

[Chemomab Therapeutics @ChemomabTx]

Recently presented SPRING trial data from Digestive Disease Week® 2025 confirms the clinical potential of nebokitug as a first-in-class novel treatment for primary sclerosing cholangitis (PSC) and supports advancement to Phase 3. Read more: https://t.co/7zm5UjFOwK $CMMB #DDW25

[Chemomab Therapeutics @ChemomabTx]

Chemomab today announced that data from our Ph.2 SPRING trial of nebokitug (CM-101) in primary sclerosing cholangitis (PSC) was presented in a Distinguished Abstract Plenary session at Digestive Disease Week® 2025 in San Diego, CA. Read more: https://t.co/7zm5UjFOwK $CMMB #DDW25

[Chemomab Therapeutics @ChemomabTx]

Reported data from two study abstracts to be presented at the #EASLCongress further confirms the clinical potential of nebokitug as a first-in-class novel treatment for PSC and other fibro-inflammatory conditions. Read more: https://t.co/DZQS86NRWN $CMMB

[Chemomab Therapeutics @ChemomabTx]

Adi Mor, PhD, co-founder and Chief Executive Officer of Chemomab, comments on new positive clinical data that supports nebokitug's impact on primary sclerosing cholangitis (PSC) and related diseases. Read more: https://t.co/DZQS86NRWN $CMMB #EASLCongress

[Chemomab Therapeutics @ChemomabTx]

New analyses of primary sclerosing cholangitis (PSC) data from our Ph. 2 SPRING trial show that treatment with nebokitug is associated with dose-dependent and significant improvements in multiple inflammatory and fibrotic biomarkers. https://t.co/DZQS86NRWN $CMMB #EASLCongress

[Chemomab Therapeutics @ChemomabTx]

Chemomab today reported data from two study abstracts that will be presented as posters at EASL 2025, the @EASLNews #EASLCongress, that will be held May 7–10th, 2025, in Amsterdam, the Netherlands. For full details: https://t.co/DZQS86NRWN $CMMB

[Chemomab Therapeutics @ChemomabTx]

Douglas Thorburn, MD will present at @BritSocGastro the British Society of Gastroenterology’s annual meeting #BSGLIVE25, June 23–26th in Glasgow, UK, time TBD. Details: https://t.co/zghQL9U8gq $CMMB

[Chemomab Therapeutics @ChemomabTx]

Clinical data on nebokitug (CM-101) for the treatment of patients with primary sclerosing cholangitis (PSC) will be presented at multiple major upcoming scientific conferences.

For more information on the upcoming presentations, visit: https://t.co/zghQL9U8gq $CMMB

[Chemomab Therapeutics @ChemomabTx]

Adi Mor, PhD, co-founder and CEO of Chemomab, will present on May 9th, 8:30–17:30 CEDT in Amsterdam at the Annual Congress of the European Association for the Study of the Liver @EASLnews #EASLCongress.
Details: https://t.co/zghQL9U8gq $CMMB

[Chemomab Therapeutics @ChemomabTx]

We believe these two appointments position us well as we formulate next steps for advancing nebokitug. For more information, visit: https://t.co/PQPfoUe63F $CMMB

[Chemomab Therapeutics @ChemomabTx]

We are delighted to welcome Dr. Weiner back as Interim CMO. Dave was a major force in strengthening our nebokitug Ph. 2 SPRING trial in PSC, a trial that recently delivered positive results & set the stage to advance towards a Ph. 3 pivotal trial. https://t.co/PQPfoUe63F $CMMB

[Chemomab Therapeutics @ChemomabTx]

We also congratulate Mr. Lawler on his promotion to Chief Development Officer. Jack has been instrumental in our clinical progress, leading efforts to build a clinical organization that successfully implemented a global PSC clinical program & delivered positive clinical results.